HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.

AbstractOBJECTIVES:
The purpose of this study was to assess the efficacy and safety of low-dose (1 mg) daily diethylstilbestrol (DES) for the treatment of castrate-resistant prostate cancer (CRPC).
MATERIALS AND METHODS:
A retrospective chart review was performed on patients treated with low-dose DES who had CRPC despite anti-androgen withdrawal. The study population consists of 63 patients treated in the pre- and post-chemotherapy settings based on a database review; 58 had sufficient data for efficacy, all were analyzed for safety.
RESULTS:
A PSA decrease of ≥50% was observed in 19 of 49 pre-chemotherapy patients (39%) with a median time to progression (TTP) of 30 weeks (95% CI, 21.9, 68.7). A PSA decrease of <50% was seen in another 16 patients (33%) with a median TTP of 16.4 weeks (95% CI, 13.0, 37.6). Fourteen patients (29%) had progressive disease by PSA testing; their median TTP was 6.9 weeks (95% CI, 5.6, 12.9). Thromboembolic events included 2 patients with DVTs and 1 patient who developed primary fibrinolysis syndrome. Additional adverse events included gynecomastia in 37 of 63 patients (59%). Secondary observations included PSA responses in 3 of 9 patients treated with DES after chemotherapy progression and a high rate of PSA responses in patients re-treated with DES after a drug holiday.
CONCLUSIONS:
Low-dose DES is safe and effective in a modern cohort of men with CRPC despite anti-androgen treatment. Its potential role in the post-chemotherapy setting and the suggestion of efficacy on re-challenge merits additional consideration.
AuthorsJulia Clemons, L Michael Glodé, Dexiang Gao, Thomas W Flaig
JournalUrologic oncology (Urol Oncol) Vol. 31 Issue 2 Pg. 198-204 (Feb 2013) ISSN: 1873-2496 [Electronic] United States
PMID21795073 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier Inc. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Diethylstilbestrol
  • Prostate-Specific Antigen
Topics
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Diethylstilbestrol (administration & dosage, therapeutic use)
  • Drug Resistance, Neoplasm
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Prostate-Specific Antigen (blood)
  • Prostatic Neoplasms (drug therapy, mortality)
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: